NIDA Boosts Research and Development of Medical Devices for Substance use Disorder via the NIH Blueprint MedTech Initiative

Subst Use Misuse. 2023;58(5):735-738. doi: 10.1080/10826084.2023.2184209. Epub 2023 Mar 3.

Abstract

Background: Deaths from drug overdose have reached a crisis level, with more than 100,000 reported from April 2020 to April 2021. Novel approaches to address it are urgently needed. Objectives: National Institute on Drug Abuse (NIDA) is leading novel comprehensive efforts to develop safe and effective products that address the needs of the citizens affected by SUD. NIDA aims to support research and development of medical devices intended to monitor, diagnose, or treat substance use disorders. Results: NIDA participates in Blueprint MedTech program is part of the large NIH Blueprint for Neurological Research Initiative. It supports the research and development of new medical devices through product optimization, pre-clinical testing, and human subject studies, including clinical trials. The program is structured in two main components - Blueprint MedTech Incubator and Blueprint MedTech Translator. It offers free to the researcher services that are typically unavailable in academic environment - business expertise facilities and staffing to successfully develop minimum viable devices, pre-clinical bench testing, clinical studies, planning and executing in manufacturing, as well as regulatory expertise. Conclusions: Through Blueprint MedTech, NIDA provides innovators with expanded resources to ensure the success of the research.

Keywords: device development; diagnostics; regulated devices; research support; substance use disorder; treatment.

MeSH terms

  • Drug Overdose*
  • Humans
  • National Institute on Drug Abuse (U.S.)
  • Research
  • Substance-Related Disorders* / diagnosis
  • Substance-Related Disorders* / therapy
  • United States

Substances

  • N-nitrosoiminodiacetic acid